SCHEDULE 13G: Institutional Investors Disclose Significant Stake in Biodexa Pharmaceuticals Plc

A group of investment entities and individuals, including Cavalry Fund I LP and Mercer Street Global Opportunity Fund, LLC, have disclosed beneficial ownership of up to 6.8% of Biodexa Pharmaceuticals Plc's Ordinary Shares.

Summary

• Multiple investment entities and individuals, collectively referred to as 'Reporting Persons,' have filed a Schedule 13G indicating beneficial ownership in Biodexa Pharmaceuticals Plc.
• The Reporting Persons include Cavalry Fund I LP, C/M Capital Partners, LP, Cavalry Investment Fund LP, Cavalry Fund I Management LLC, Mercer Street Global Opportunity Fund, LLC, Mercer Street Capital Partners, LLC, Thomas Walsh, and Jonathan Juchno.
• As of the event date of May 20, 2025, Jonathan Juchno, as one of the Reporting Persons, beneficially owns the largest reported stake, totaling 1,752,390,000 Ordinary Shares.
• This aggregate ownership represents 6.8% of Biodexa Pharmaceuticals Plc's outstanding Ordinary Shares, based on 25,617,408,922 Ordinary Shares outstanding as of April 1, 2025.
• The Ordinary Shares have a nominal value of 0.00005 GBP per share, and the American Depositary Shares (ADSs) are quoted on The Nasdaq Capital Market under the symbol 'BDRX,' with each ADS representing 10,000 Ordinary Shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of passive beneficial ownership by institutional investors in a publicly traded pharmaceutical company. It does not provide specific insights into broader industry trends or competitive positioning, but rather indicates a significant investment by a group of funds and individuals in Biodexa Pharmaceuticals Plc.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by institutional investors may be viewed as a vote of confidence or increased liquidity for the stock, though it does not imply active management influence.

Key Dates

Keywords

Biodexa Pharmaceuticals Plc, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investors, BDRX, Ordinary Shares, American Depositary Shares, Cavalry Fund I LP, Mercer Street Global Opportunity Fund, LLC